Program
regorafenib
Also written as “Regorafenib (Stivarga, BAY73-4506)”, “Regorafenib” and “Regorafenib (BAY73-4506)”.
Its studies are mostly in Colorectal Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Pancreatic Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 321 open or running | phase 4since May 24, 2018 | Apr 17, 2008 | Apr 27, 2028phase 2 · NCT06246643 |
| Sarah Cannon Research Institute | 10 open or running | phase 2since Apr 21, 2015 | Apr 21, 2015 | none ahead |
Also a collaborator on its studies: Novartis, Merck, Bristol-Myers Squibb and bayer-healthcare-pharmaceuticals-inc-bayer-schering-pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Apr 17, 2008.
- Oct 28, 2013Phase 1 study in NeoplasmsBayer · NCT01973868 · 42 enrolled · United States
- Nov 28, 2013Phase 1 study in NeoplasmsBayer · NCT02001909 · 27 enrolled · Germany
- Mar 7, 2014Phase 1 study in NeoplasmsBayer · NCT02085148 · 62 enrolled · France, Italy, Spain and more
- Apr 4, 2014Phase 1 study in NeoplasmsBayer · NCT02106845 · 42 enrolled · Germany, Hungary
- Aug 20, 2014Phase 2 study in Macular DegenerationBayer · NCT02222207 · 52 enrolled · United States, Australia, Austria and more
- Mar 20, 2015Phase 1 study in NeoplasmsBayer · NCT02398513 · 18 enrolled · China
- Apr 21, 2015Sarah Cannon Research Institute's first study: phase 2 study in Colorectal NeoplasmsNew to Sarah Cannon Research InstituteSarah Cannon Research Institute · NCT02425683 · 24 enrolled · United States
- Jun 4, 2015Phase 2 study in Colorectal NeoplasmsBayer · NCT02465502 · 59 enrolled · Brazil
- Nov 16, 2017Phase 1 study in Carcinoma, HepatocellularBayer · NCT03347292 · 58 enrolled · United States, Germany
- May 24, 2018Phase 4 study in Colorectal NeoplasmsBayer · NCT03564938 · 100 enrolled · India
- Mar 25, 2019Phase 2 study in Colorectal NeoplasmsBayer · NCT03890731 · 6 enrolled · United States, Germany, Italy and more
- Oct 11, 2019Phase 2 study in Colorectal NeoplasmsBayer · NCT04126733 · 70 enrolled · United States
- Jan 4, 20212 phase 2 studiesBayer · NCT04696055, NCT04704154
- Jan 14, 2024Phase 2 study in Solid Malignant TumorsBayer · NCT06246643 · 13 enrolled · France, Japan, South Korea and more
Ahead
- Apr 27, 2028Primary completion: phase 2 study in Solid Malignant TumorsBayer · NCT06246643
TargetBeta
“Tyrosine-protein kinase ABL inhibitor; Serine/threonine-protein kinase RAF inhibitor; Stem cell growth factor receptor inhibitor; Fibroblast growth factor receptor 1 inhibitor”ChEMBL 37, by rule
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06246643Solid Malignant Tumors · France, Japan, South Korea and more | 2 | Active, not recruiting | Bayer | Apr 27, 2028 | 13 |
| NCT04704154Squamous Cell Carcinoma of Head and Neck · United States, Belgium, France and more | 2 | Completed | Bayer | Mar 9, 2023 | 175 |
| NCT04696055Carcinoma, Hepatocellular · United States, France, Germany and more | 2 | Completed | Bayer | May 5, 2022 | 95 |
| NCT04126733Colorectal Neoplasms · United States | 2 | Completed | Bayer | Nov 11, 2020 | 70 |
| NCT03890731Colorectal Neoplasms · United States, Germany, Italy and more | 2 | Completed | Bayer | Feb 28, 2023 | 6 |
| NCT03564938Colorectal Neoplasms · India | 4 | Completed | Bayer | Mar 20, 2023 | 100 |
| NCT03347292Carcinoma, Hepatocellular · United States, Germany | 1 | Completed | Bayer | Dec 17, 2020 | 58 |
| NCT02465502Colorectal Neoplasms · Brazil | 2 | Completed | Bayer | May 2, 2017 | 59 |
| NCT02425683Colorectal Neoplasms · United States | 2 | Terminated | Sarah Cannon Research Institute | Sep 21, 2017 | 24 |
| NCT02398513Neoplasms · China | 1 | Completed | Bayer | Nov 2015 | 18 |
| NCT02222207Macular Degeneration · United States, Australia, Austria and more | 2 | Terminated | Bayer | May 2015 | 52 |
| NCT02106845Neoplasms · Germany, Hungary | 1 | Completed | Bayer | Apr 27, 2015 | 42 |
| NCT02085148Neoplasms · France, Italy, Spain and more | 1 | Completed | Bayer | May 5, 2019 | 62 |
| NCT02001909Neoplasms · Germany | 1 | Completed | Bayer | Apr 2014 | 27 |
| NCT01973868Neoplasms · United States | 1 | Completed | Bayer | Jan 31, 2017 | 42 |
| NCT01939223Colorectal Neoplasms · United States, Australia, Belgium and more | 3 | Terminated | Bayer | Aug 29, 2016 | 25 |
| NCT01853046Neoplasms · United States, Canada | 1 | Completed | Bayer | Jul 2015 | 24 |
| NCT01853319Colorectal Neoplasms · Turkey | 3 | Completed | Bayer | Apr 24, 2015 | 100 |
| NCT01774344Carcinoma, Hepatocellular · United States, Argentina, Australia and more | 3 | Completed | Bayer | Feb 29, 2016 | 573 |
| NCT01584830Colorectal Neoplasms · China, Hong Kong, Korea, Republic of and more | 3 | Completed | Bayer | Nov 2013 | 204 |
| NCT01339104Neoplasms · United States | 1 | Completed | Bayer | Aug 2013 | 53 |
| NCT01318265Pharmacokinetics · United States | 1 | Completed | Bayer | Jul 2011 | 24 |
| NCT01289821Colorectal Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Bayer | Mar 2012 | 54 |
| NCT01271712Gastrointestinal Stromal Tumors · United States, Austria, Belgium and more | 3 | Completed | Bayer | Jan 26, 2012 | 199 |
| NCT01187615Small Cell Lung Carcinoma · United States | 1 | Terminated | Bayer | Jun 2012 | 9 |
| NCT01103323Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Bayer | Jul 2011 | 760 |
| NCT01096030Neoplasms · Hong Kong, Singapore | 1 | Completed | Bayer | Nov 2012 | 33 |
| NCT01117623Neoplasms · United States | 1 | Completed | Bayer | Nov 2013 | 86 |
| NCT01002378Dietary Fats · United States | 1 | Completed | Bayer | Feb 2010 | 24 |
| NCT01003015Carcinoma, Hepatocellular · Germany, Italy, Korea, Republic of and more | 2 | Completed | Bayer | Nov 2010 | 36 |
| NCT00960258Neoplasms · Japan | 1 | Completed | Bayer | Apr 26, 2010 | 15 |
| NCT00934882Colorectal Neoplasms · Germany | 1 | Completed | Bayer | Apr 2012 | 45 |
| NCT00664326Carcinoma, Renal Cell · United States, Finland, France and more | 2 | Completed | Bayer | May 31, 2009 | 49 |
How it is read
Names in the registry
- “Regorafenib (Stivarga, BAY73-4506)”, 21 entries
- “Regorafenib”, 6 entries
- “Regorafenib (BAY73-4506)”, 4 entries
- “TAS-102, Regorafenib , Fruquintinib”, 1 entry
- “Regorafenib, (Stivarga, BAY73-4506)”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 16 studies
- Neoplasms, 10 studies
- Carcinoma, Hepatocellular, 5 studies
- Pancreatic Neoplasms, 1 study
- Squamous Cell Carcinoma of Head and Neck, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.